While a company is not composed of one man, a good deal of
its success (or failure) can be attributed to its leadership. One company has
been led by a single individual for most of its over 20 years of existence. He
is not a founder but has guided the company to continued growth and
profitability.
John C. Martin
joined Gilead Sciences in 1990 in a senior role. By 1996 he became the President and CEO until
2008 when he became Chairman of the Board of Directors and CEO until present.
Since Gilead was established in 1987, it can be said that for most of the
company’s existence Martin has been its head.
His stewardship has led the company to significant growth.
With his vision and focus on
antiviral research Gilead has a leading market share in drug treatment for hepatitis
B, influenza, and HIV. The company has likewise gained leadership in offering
access to low cost HIV medications in developing countries.
Gilead
is a research-based biopharmaceutical company. It discovers and develops
medicine with the aim of commercializing it. Its’ annual revenue in 2011 reached
around $8.4 billion and the company has been cited in many publications for its
strong business performance. The company
has 14 marketed products and has about 4,500 employees with offices in four
continents. Its products can be
categorized in the following areas: HIV/AIDS, Liver Disease, Cardiovascular,
Respiratory, and others.
Martin’s performance as head of the company has not gone
unnoticed. Publications like Chief Executive.net
rank him as one of the top 10 most valuable CEO. Prior to joining Gilead,
Martin held high positions at Bristol-Myers Squibb and Syntex Corporation.
Aside for his job experience, his academic background is quite suited to his
work; he has an MBA in marketing from Golden State University and a PhD in
organic chemistry from the University of Chicago.
The company’s continued growth and profitability is a
reflection of Martin’s excellent leadership in running Gilead Science, Inc.
No comments:
Post a Comment